A Multicenter Phase II Study of Irinotecan and Alvocidib (Flavopiridol)
versus Irinotecan Alone for Patients with p53 Wild-Type Gastric Adenocarcinoma Whose Disease Has Progressed on One Line of Treatment
[Protocol 09-074] |
Janjigian, Yelena, MD |
A Phase IB Study of BKM120 plus MEK162 in Select Patients with Advanced Solid Tumors
[Protocol 11-117] |
Schwartz, Gary, MD |
A Phase II Study of CO-1.01 for Gemcitabine-Refractory Patients with Stage IV Pancreatic Cancer
[Protocol 10-210] |
O'Reilly, Eileen, MD |
A Phase II Study of FOLFOX with or without GDC-0449 in Patients with Advanced Gastric and Gastroesophageal Junction Carcinoma
[Protocol 10-109] |
Janjigian, Yelena, MD |
A Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin in Patients with Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
[Protocol 07-113] |
O'Reilly, Eileen, MD |
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Pancreatic Cancer
[Protocol 10-083] |
Goodman, Karyn, MD |
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
[Protocol 11-194] |
Ginex, Pamela, RN, EDD |
A Randomized Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) Treatment versus Conventional DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer
[Protocol 06-103] |
Janjigian, Yelena, MD |
Early Onset and Familial Gastric Cancer Registry
[Protocol 05-118] |
Kelsen, David, MD |
Memorial Sloan-Kettering Cancer Center Pancreatic Tumor Registry
[Protocol 02-102] |
Kurtz, Robert, MD |
Phase II Trial of Sorafenib for Patients with Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
[Protocol 09-016] |
Ilson, David, MD |
